Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 13/20 | 0.62 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3434953 | 0.88 | CYP11B1 (0.53) | CYP11B1CYP11B2CYP19A1KDM4EHSD17B10 | |
| SCHEMBL30168127 | 0.88 | CYP11B1 (0.62) | CYP11B1CYP11B2CYP19A1KDM4EHSD17B10 | |
| SCHEMBL5849720 | 0.84 | CYP11B1 (0.66) | CYP11B1CYP11B2CYP19A1KDM4EHSD17B10 | |
| SCHEMBL5610972 | 0.84 | CYP11B1 (0.60) | CYP11B1CYP11B2CYP19A1POLB | |
| SCHEMBL5610709 | 0.81 | CYP11B1 (0.54) | CYP11B1CYP11B2CYP19A1KDM4EHSD17B10 | |
| SCHEMBL5592277 | 0.81 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP19A1KDM4EPOLB | |
| SCHEMBL14473080 | 0.81 | CYP11B1 (0.53) | CYP11B1CYP11B2CYP19A1ALDH1A1POLB | |
| SCHEMBL14473081 | 0.81 | CYP11B1 (0.53) | CYP11B1CYP11B2CYP19A1ALDH1A1POLB | |
| SCHEMBL3401688 | 0.80 | KMT2A (0.48) | CYP11B1CYP11B2CYP19A1KDM4EALDH1A1 | |
| SCHEMBL5592268 | 0.79 | IDH1 (0.55) | CYP11B1CYP11B2CYP19A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101981036-B | Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG | 2013-09-04 | — | — | CN | disclosed |
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| CN-101981036-A | Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG | 2011-02-23 | — | — | CN | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | CYP11B1 224/4885CYP11B2 205/4885CYP19A1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.